A Hyderabad-based vaccine and pharmaceutical company announced the initiation of a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India.
This early-stage study’s results are expected to be available by February 2021.
India and Texas Partner to Develop COVID-19 Vaccine
AKI Common in U.S. Veterans Hospitalized With COVID-19
AKI associated with increased odds of mechanical ventilation use, longer hospital stay, increased risk for death
OCD Symptoms Worsening Among Children During COVID-19
Worsening was most pronounced among children with early age of onset, family history of ADHD